Lantheus stock is trading -28.11% below its average target price of $122.38 after dropping -3.1% during today's morning session. Analysts are giving the mid-cap Biotechnology company an average rating of buy and target prices ranging from $113.0 to $130.0 per share.
The stock has an above average percentage of its shares sold short at 10.0%, and a short ratio of 4.55. Since 2.81% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 101.3% of Lantheus's shares being owned by this investor type.
Institutions Invested in Lantheus
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Blackrock Inc. | 11% | 7,807,737 | $686,963,744 |
| 2023-03-31 | Vanguard Group Inc | 11% | 7,353,063 | $646,959,252 |
| 2023-03-31 | Alliancebernstein L.p. | 4% | 2,845,605 | $250,370,557 |
| 2023-03-31 | State Street Corporation | 3% | 2,324,952 | $204,560,903 |
| 2023-03-31 | Hood River Capital Management LLC | 2% | 1,633,626 | $143,734,584 |
| 2023-03-31 | Assenagon Asset Management S.A. | 2% | 1,454,887 | $128,008,233 |
| 2023-03-31 | Invesco Ltd. | 2% | 1,419,040 | $124,854,235 |
| 2023-03-31 | Dimensional Fund Advisors LP | 2% | 1,386,612 | $122,001,057 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 1,345,272 | $118,363,757 |
| 2023-03-31 | Price (T.Rowe) Associates Inc | 2% | 1,291,460 | $113,629,108 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Lantheus.
